Kuros Biosciences AG (KURN) - Total Liabilities
Based on the latest financial reports, Kuros Biosciences AG (KURN) has total liabilities worth CHF40.28 Million CHF (≈ $50.93 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kuros Biosciences AG - Total Liabilities Trend (2004–2025)
This chart illustrates how Kuros Biosciences AG's total liabilities have evolved over time, based on quarterly financial data. See KURN working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Kuros Biosciences AG Competitors by Total Liabilities
The table below lists competitors of Kuros Biosciences AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Quanex Building Products
NYSE:NX
|
USA | $1.27 Billion |
|
Sgis Songshan Co Ltd
SHE:000717
|
China | CN¥12.19 Billion |
|
Changhong Meiling Co Ltd
SHE:000521
|
China | CN¥17.44 Billion |
|
Ridley Corporation Ltd
AU:RIC
|
Australia | AU$1.10 Billion |
|
Fox Factory Holding Corp
NASDAQ:FOXF
|
USA | $1.02 Billion |
|
Swissquote Group Holding SA
SW:SQN
|
Switzerland | CHF14.65 Billion |
|
Shaanxi Construction Machinery Co Ltd
SHG:600984
|
China | CN¥11.18 Billion |
|
China Fortune Land Development Co Ltd
SHG:600340
|
China | CN¥259.93 Billion |
Liability Composition Analysis (2004–2025)
This chart breaks down Kuros Biosciences AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Kuros Biosciences AG market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kuros Biosciences AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kuros Biosciences AG (2004–2025)
The table below shows the annual total liabilities of Kuros Biosciences AG from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CHF40.28 Million ≈ $50.93 Million |
+56.20% |
| 2024-12-31 | CHF25.79 Million ≈ $32.61 Million |
+74.82% |
| 2023-12-31 | CHF14.75 Million ≈ $18.65 Million |
+4.73% |
| 2022-12-31 | CHF14.09 Million ≈ $17.81 Million |
-1.91% |
| 2021-12-31 | CHF14.36 Million ≈ $18.15 Million |
+47.09% |
| 2020-12-31 | CHF9.76 Million ≈ $12.34 Million |
-2.34% |
| 2019-12-31 | CHF10.00 Million ≈ $12.64 Million |
+7.06% |
| 2018-12-31 | CHF9.34 Million ≈ $11.81 Million |
-27.84% |
| 2017-12-31 | CHF12.94 Million ≈ $16.36 Million |
+137.62% |
| 2016-12-31 | CHF5.45 Million ≈ $6.89 Million |
+110.27% |
| 2015-12-31 | CHF2.59 Million ≈ $3.27 Million |
-94.09% |
| 2014-12-31 | CHF43.85 Million ≈ $55.44 Million |
+20.89% |
| 2013-12-31 | CHF36.27 Million ≈ $45.86 Million |
+78.14% |
| 2012-12-31 | CHF20.36 Million ≈ $25.74 Million |
-52.08% |
| 2011-12-31 | CHF42.49 Million ≈ $53.72 Million |
-10.50% |
| 2010-12-31 | CHF47.48 Million ≈ $60.02 Million |
-21.48% |
| 2009-12-31 | CHF60.46 Million ≈ $76.44 Million |
-23.37% |
| 2008-12-31 | CHF78.89 Million ≈ $99.74 Million |
+14.13% |
| 2007-12-31 | CHF69.12 Million ≈ $87.39 Million |
+500.46% |
| 2006-12-31 | CHF11.51 Million ≈ $14.55 Million |
+37.33% |
| 2005-12-31 | CHF8.38 Million ≈ $10.60 Million |
+2.34% |
| 2004-12-31 | CHF8.19 Million ≈ $10.36 Million |
-- |
About Kuros Biosciences AG
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Granules, an advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; Ma… Read more